AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

latest news and events


December 2017

AROMICS partipates at the SME Capital Forum

Closing the year with the company presentacion at the 32 editiion of

mas noticias


September 2017

Dr. Lombardi will present recent advances on berberine antitumor agents at the 15th IDDST 2017 meeting

Dr. Paolo Lombardi, CEO of Naxospharma, a close collaborator of AROMICS, will give...

mas noticias


With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.

John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.